Please ensure Javascript is enabled for purposes of website accessibility

Why Proto Labs Stock Popped 13%, Then Gave Almost All of It Back

By Rich Smith - Updated Apr 30, 2020 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pro forma earnings were great, GAAP earnings weren't.

What happened

Great was the rejoicing when contract 3D-printing manufacturer Proto Labs (PRLB 1.17%) reported its big "earnings beat" this morning -- great,  and temporary.

Before trading opened for the day, Proto Labs, which uses additive manufacturing to produce industrial prototypes and production parts for its customers, reported that its pro forma earnings for the fiscal first quarter 2020 came in at $0.61 per share, well above the $0.38 that Wall Street had predicted. (Sales of $115 million likewise trumped predictions for just $102 million in the quarter.)  

At first, this news sent Proto Labs stock flying up 12.8% in early trading. But here at the market close, it had just a 4% gain.

Chalkboard drawing of stock chart arrow going up being erased and pointing back down

Image source: Getty Images.

So what

Proto Labs may have beaten sales estimates, but its $115 million in Q1 revenue was up only 1.5% year over year. The company's pro forma profit of $0.61 was great, no doubt, and another beat. But actual GAAP earnings were only $0.52 per share, down 9% from last year's Q1.  

The primary reason for the weak sales growth and weaker profits was the coronavirus pandemic. "During the first two and a half months of the first quarter of 2020, ordering trends were in line with our expectations," CEO Vicki Holt said. But by mid-March, she said, "as the global pandemic intensified and economic activity declined, ordering activity slowed." 

Now what

And what will April, May, and the months beyond hold for Proto Labs? Here, the news is both bad and good. On the one hand, "the ultimate financial impact of the COVID-19 pandemic is unknown at this time," CFO John Way says. On the other hand, as early as late March, immediately following the coronavirus-inspired sales slowdown, Holt says, the company "began to receive orders for COVID-19 related parts --primarily injection molding in the Americas -- which helped mitigate the slowdown in other services and regions." 

Whether this influx of new business in emergency-printing parts for use in treating the coronavirus will offset what looks like a very serious slowdown in mid-March, and get Proto Labs growing faster than single digits again in Q2, remains to be seen.

For now, analysts are forecasting a staggering 70% decline in profits in Q2. But if Proto Labs manages to pull off an upset, you can expect Wall Street analysts to be even more surprised next quarter than they were in this one.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Proto Labs, Inc. Stock Quote
Proto Labs, Inc.
PRLB
$48.40 (1.17%) $0.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.